= Discovery stage. (16.60%, 2024)
= Translation stage. (37.02%, 2024)
= Clinically available. (46.38%, 2024)
MSACL 2024 : Session

MSACL 2024 Abstract

Self-Classified Topic Area(s): Small Molecule > none > none
Discussion on Impending FDA Regulation of Clinical Lab LDTs

Discussion Session (Presenter)

Relevant Financial Disclosures (within past 24 months, reported on Jan 31, 2024)
No relevant financial relationship(s) to disclose.
Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above.
Conflict mitigation NOT REQUIRED.

Abstract

Panel Discussion with Stephen Master, Andy Hoofnagle, Gwen McMillan, Dennis Dietzen and Kara Lynch.